Topics:

NCCN Updates its Treatment Guidelines for Breast Cancer

NCCN Updates its Treatment Guidelines for Breast Cancer

HOLLYWOOD, Florida—The 2002 National Comprehensive Cancer Network (NCCN)
breast cancer treatment guidelines include a number of important updates
regarding the use of aromatase inhibitors, leuteinizing hormone-releasing
hormone (LHRH) agonists, and sentinel lymph node biopsy. Robert W. Carlson, MD,
chair of the NCCN Breast Cancer Panel, presented the guidelines at the Seventh
Annual NCCN Conference.

Based on results of the large, randomized Arimidex, Tamoxifen Alone or in
Combination (ATAC) trial, the panel elected to
add a footnote to the guidelines for systemic adjuvant therapy of
hormone-receptor-positive postmenopausal women with node-negative stage I-IIB
disease (larger than 1 cm).

The footnote states that the selective aromatase inhibitor anastrozole (Arimidex)
is an option to tamoxifen (Nolvadex) in this setting, pending further
long-term evidence of anastrozole’s efficacy and safety.

ATAC showed a 17% reduction in risk of recurrence with the use of
anastrozole (22% reduction in hormone-sensitive patients). The footnote states
that "at the current time, anastrozole can be considered an option to
tamoxifen after discussion of available data between physician and patient.
These data do not address whether women currently on tamoxifen should be
changed to anastrozole. Anastrozole is not appropriate for premenopausal
women."

"The reason that we have left the two drugs as equivalent," said
Dr. Carlson, professor of medicine and medical informatics, Stanford
University, "is that we have 25 years of experience with tamoxifen. The
aromatase inhibitors have been licensed since 1995 (anastrozole) and 1996 (letrozole
[Femara]), so we don’t have long-term data on toxicities."

In the ATAC trial, anastrozole was also superior in reducing the incidence
of contralateral breast cancers, with a 58% reduction. "This is a
relatively remarkable result," Dr. Carlson said, "and it will be
really important if it holds up, because we already know from the Breast Cancer
Prevention Trial that tamoxifen reduces the risk of contralateral breast cancer
by 50%. If we’re now seeing an additional 58% reduction, that’s an enormous
risk reduction that could potentially be moved into the breast cancer
prevention setting."

The new guidelines also upgraded the use of anastrozole and letrozole as
equal to tamoxifen as first-line therapy for postmenopausal women with
hormone-responsive recurrent breast cancer and no prior hormonal therapy. Dr.
Carlson referred to two randomized trials of anastrozole vs tamoxifen in this
setting that included more than 1,000 patients (J Clin Oncol 18:3748, 3758,
2000). The studies showed equivalence or superiority to tamoxifen in time to
progression.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.